The sensor to participate in the 2nd Annual LifeSci Partners Genetics Symposium on June 29, 2022

Montpellier, France, June 24, 2022– (work wire) – Regulatory news:

Sensors (FR0012596468 – ALSEN) (Paris:ALSEN) A leading clinical-stage biotechnology company that specializes in developing novel therapies for the recovery, treatment and prevention of hearing loss disorders, is pleased to announce the participation of CEO Nawal Ozren in LifeSci Partners 2second abbreviation The Annual Symposium on Genetic Medicines takes place approximately 28-29 June 2022.

CEO Nawal Ozren will share a chat with Jeff Goodenburg as part of LifeSci Partners 2second abbreviation Annual Symposium on Genetic Medicineson June 29, 2022. To attend the discussion, please register over here. A side chat replay will be available shortly after the presentation ends at the same time Link.

Date: Wednesday 29 June 2022
next to the fireplace chat: 8.30 a.m. – 9 a.m. EST (2.30 p.m. – 3 p.m. CST)
EventLifeSci 2 . Partnerssecond abbreviation Annual Symposium on Genetic Medicines

About Sensor

Sensorion is a leading clinical-stage biotechnology company that specializes in developing new therapies to restore, treat and prevent hearing loss disorders, a significant unmet global medical need.

Sensorion has built a unique research and development technology platform to expand its understanding of the pathophysiology and etiology of the inner ear, enabling it to select the best targets and methods for drug candidates. Her portfolio combines small molecule programs with a preclinical portfolio of inner ear genetic therapies.

Its clinical phase portfolio includes one Phase II product: SENS-401 (Arazasetron) progressing in a planned, proof-of-concept phase II clinical study of SENS-401 in cisplatin-induced ototoxicity (CIO) and with partner Cochlear Limited, a study of SENS-401 in Patients scheduled for cochlear implantation.

Sensorion has entered into a broad strategic collaboration with the Pasteur Institute focusing on the genetics of audiology. It contains two gene therapy programs aimed at correcting single-gene genetic forms of deafness including deafness caused by a mutation in the gene coding for Otoferlin, and hearing loss associated with a mutation in the GJB2 gene to address important hearing loss segments in adults and children. The company is also working to identify biomarkers to improve the diagnosis of these underserved diseases.

a poster: sensor
inside: FR0012596468
mnemonic: ALSEEN


This press release contains certain forward-looking statements regarding Sensorion and its business. These forward-looking statements are based on assumptions that Sensorion considers reasonable. However, there can be no guarantee that such forward-looking statements will be verified, which are subject to numerous risks, including those set forth in the Full Year 2021 Financial Report published on April 28, 2022 and available on our website and to developing circumstances. Economic, Financial Markets and Markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks that are not yet known to Sensorion or not currently considered by Sensorion. The occurrence of all or part of these risks could cause Sensorion’s actual results, financial conditions, performance or achievements to be materially different from such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or subscribe or a solicitation of an offer to buy or subscribe for the shares of Sensorion in any country. Relaying this press release in some countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform themselves of and comply with any such local restrictions.

View source version on


Investor Relations
Catherine Levo
Head of Investor Relations and Communication
+33 6 72 18 00 22

International Media Relations
Consilium Strategic Communications
Mary Jane Elliott / Jessica Hodgson
+44 7739 788014
+44 7561 424788